CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis
Open Access
- 1 October 2022
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 41 (45) , 4929-4940
Abstract
Cisplatin, 5FU and docetaxel (TPF) are the most common chemotherapy regimen used for advanced OSCC. However, many cancer patients experience relapse, continued tumor growth, and spread due to drug resistance, which leads to treatment failure and metastatic disease. Here, using a CRISPR/Cas9 based kinome knockout screening, Misshapen-like kinase 1 (MINK1) is identified as an important mediator of 5FU resistance in OSCC. Analysis of clinical samples demonstrated significantly higher MINK1 expression in the tumor tissues of chemotherapy non-responders as compared to chemotherapy responders. The nude mice and zebrafish xenograft experiments indicate that knocking out MINK1 restores 5FU mediated cell death in chemoresistant OSCC. An antibody based phosphorylation array screen revealed MINK1 as a negative regulator of p53. Mechanistically, MINK1 modulates AKT phosphorylation at Ser473, which enables p-MDM2 (Ser 166) mediated degradation of p53. We also identified lestaurtinib as a potent inhibitor of MINK1 kinase activity. The patient derived TPF resistant cell based xenograft data suggest that lestaurtinib restores 5FU sensitivity and facilitates a significant reduction of tumor burden. Overall, our study suggests that MINK1 is a major driver of 5FU resistance in OSCC. The novel combination of MINK1 inhibitor lestaurtinib and 5FU needs further clinical investigation in advanced OSCC.Keywords
All Related Versions
Funding Information
- Indian Council of Medical Research (5/13/9/2019-NCD-III)
- Department of Biotechnology, Ministry of Science and Technology (BT/ INF/22/SP28293/2018)
This publication has 25 references indexed in Scilit:
- Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A ReassessmentHuman Mutation, 2014
- Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedsideExpert Opinion on Investigational Drugs, 2010
- Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disordersBlood, 2008
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosisOncogene, 2002
- A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleusProceedings of the National Academy of Sciences, 2001
- Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53Cancer Gene Therapy, 2000
- The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53Oncogene, 1999
- DNA damage activates p53 through a phosphorylation–acetylation cascadeGenes & Development, 1998
- Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes expressing mutant p53Oral Oncology, 1995